ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,903, issued on July 15, was assigned to Gilead Sciences Inc. (Foster City, Calif.).
"FXR (NR1H4) modulating compounds" was invented by Peter A. Blomgren (Issaquah, Wash.), Kevin S. Currie (North Bend, Wash.), Julie Farand (San Mateo, Calif.), Christian Gege (Mauer, Germany), Jeffrey E. Kropf (Issaquah, Wash.) and Jianjun Xu (Bellevue, Wash.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions thr...